Article

B+L names CMO

Bausch + Lomb has appointed Calvin W. Roberts, MD, to the newly created position of chief medical officer.

Rochester, NY-Bausch + Lomb (B+L) has appointed Calvin W. Roberts, MD, to the newly created position of chief medical officer. He will be a member of the executive leadership team and will coordinate the company’s global research and development efforts across the company’s vision care, pharmaceuticals, and surgical business units.

A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing and producing over-the-counter products for vision care, prescription ocular therapeutics, and treatment regimens. He is considered to be the “father” of ophthalmic non-steroidals and has published 50 peer-reviewed articles, according to his new employer.

“As a renowned expert in ophthalmology and the development of eye-health products, Cal is uniquely qualified to help us further strengthen product innovation, benefiting our customers and their patients around the world,” said Brent Saunders, chief executive officer of B+L.

Dr. Roberts is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003. He also is a clinical professor of ophthalmology at Weill Medical College of Cornell University.

Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and is the developer of instruments for cataract surgery. As a consultant to ophthalmic pharmaceutical companies, including Allergan Pharmaceuticals, Johnson and Johnson, and Novartis, he has helped lead the development and marketing efforts for several new therapeutics.

“I look forward to bringing the perspective of clinical optometrists and ophthalmologists to the development of new, innovative products to benefit our patients,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.